MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, reports that Merck KGaA signed a definitive agreement to acquire the chromatography business of JSR Life Sciences, a CDMO focusing on preclinical and translational clinical research and bioprocessing solutions.
The acquisition will expand the company’s downstream processing portfolio with advanced Protein A chromatography capabilities, supporting more efficient and scalable production of biopharmaceutical therapies, including monoclonal antibodies, according to Sebastián Arana, head of process solutions, Life Science business of Merck KGaA. The transaction is expected to close by the end of the second quarter of 2026.
“This acquisition will strengthen our position in the bioprocessing market and underscores our commitment to long-term investment in monoclonal antibody production technologies,” said Arana. “By combining JSR’s Protein A expertise with our portfolio, we can further enable customers to advance the speed, efficiency, and reliability of antibody therapy production.”
Based in Belgium, the chromatography business of JSR Life Sciences has more than 50 employees and supplies chromatography solutions to pharmaceutical and biotech manufacturers worldwide. The company is known for its Amsphere A3 and Amsphere A+ Protein A resins, which purify a wide range of monoclonal antibodies.
“This acquisition positions our innovative Amsphere Protein A technologies for even greater global impact under Merck KGaA’s platform—enabling more customers worldwide to accelerate therapies to market with enhanced speed and confidence,” said Tim Lowery, president of JSR Life Sciences.
The post MilliporeSigma to Acquire Chromatography Business of JSR Life Sciences appeared first on GEN – Genetic Engineering and Biotechnology News.
